tiprankstipranks
Advertisement
Advertisement

HK:1477 Stock Latest News

Ocumension Enrolls First Patient in China Phase III Trial for FDA-Approved Dry Eye Drug OT-211
Company AnnouncementsOcumension Enrolls First Patient in China Phase III Trial for FDA-Approved Dry Eye Drug OT-211
11d ago
1477
Ocumension Nearly Doubles Revenue in 2025 and Turns EBITDA Positive on Ophthalmic Portfolio Growth
PremiumCompany Announcements
Ocumension Nearly Doubles Revenue in 2025 and Turns EBITDA Positive on Ophthalmic Portfolio Growth
15d ago
1477
Ocumension Plans Board Refresh With New Independent Director After Wu’s Retirement
PremiumCompany Announcements
Ocumension Plans Board Refresh With New Independent Director After Wu’s Retirement
15d ago
1477
Ocumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend
PremiumCompany Announcements
Ocumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend
1M ago
1477
Ocumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan
PremiumCompany Announcements
Ocumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan
3M ago
1477
Ocumension Increases Treasury Share Holdings to Nearly 21 Million
PremiumCompany AnnouncementsOcumension Increases Treasury Share Holdings to Nearly 21 Million
4M ago
1477
Ocumension Therapeutics Gains Approval for OT-702 in China
Premium
Company Announcements
Ocumension Therapeutics Gains Approval for OT-702 in China
4M ago
1477
Ocumension Therapeutics Reports Strong Revenue Growth Amid Product Expansion
Premium
Company Announcements
Ocumension Therapeutics Reports Strong Revenue Growth Amid Product Expansion
8M ago
1477
Ocumension’s OT-301 Achieves Key Milestone in Phase III Trial
PremiumCompany Announcements
Ocumension’s OT-301 Achieves Key Milestone in Phase III Trial
8M ago
1477
Ocumension Therapeutics to Review Interim Results in Upcoming Board Meeting
PremiumCompany Announcements
Ocumension Therapeutics to Review Interim Results in Upcoming Board Meeting
8M ago
1477
Ocumension Therapeutics Updates Nomination Committee
PremiumCompany Announcements
Ocumension Therapeutics Updates Nomination Committee
9M ago
1477
Ocumension Therapeutics Announces Board Composition and Roles
PremiumCompany Announcements
Ocumension Therapeutics Announces Board Composition and Roles
9M ago
1477
Ocumension Therapeutics Updates Nomination Committee Terms
PremiumCompany AnnouncementsOcumension Therapeutics Updates Nomination Committee Terms
9M ago
1477
Promising Outlook for Ocumension Therapeutics: Buy Rating Backed by Strategic Developments and Regulatory Milestones
Premium
Ratings
Promising Outlook for Ocumension Therapeutics: Buy Rating Backed by Strategic Developments and Regulatory Milestones
10M ago
Ocumension Therapeutics Revamps Share Option Scheme to Boost Employee Incentives
Premium
Company Announcements
Ocumension Therapeutics Revamps Share Option Scheme to Boost Employee Incentives
10M ago
1477
Ocumension Therapeutics Successfully Passes All AGM Resolutions
PremiumCompany Announcements
Ocumension Therapeutics Successfully Passes All AGM Resolutions
10M ago
1477
Ocumension Therapeutics Gains Approval for Phase III Trial of Presbyopia Treatment in China
PremiumCompany Announcements
Ocumension Therapeutics Gains Approval for Phase III Trial of Presbyopia Treatment in China
10M ago
1477
Ocumension’s OT-703 Approved for Study in Hainan
PremiumCompany Announcements
Ocumension’s OT-703 Approved for Study in Hainan
11M ago
1477
Ocumension Therapeutics Announces 2025 Annual General Meeting
PremiumCompany Announcements
Ocumension Therapeutics Announces 2025 Annual General Meeting
12M ago
1477
Ocumension Therapeutics Proposes Amendments to Optimize Operations
PremiumCompany AnnouncementsOcumension Therapeutics Proposes Amendments to Optimize Operations
1y ago
1477
Ocumension Therapeutics Reports Significant Revenue Growth and Strategic Advancements in 2024
Premium
Company Announcements
Ocumension Therapeutics Reports Significant Revenue Growth and Strategic Advancements in 2024
1y ago
1477
Ocumension Therapeutics to Review Annual Financial Results and Dividend Proposal
Premium
Company Announcements
Ocumension Therapeutics to Review Annual Financial Results and Dividend Proposal
1y ago
1477

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >